⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4016272 | 0.76 | — | — | |
| SCHEMBL11004836 | 0.73 | — | — | |
| SCHEMBL1231792 | 0.73 | ATAD2 (0.37) | — | |
| Thymine SCHEMBL4152636 | 0.73 | — | — | |
| SCHEMBL8194730 | 0.73 | — | — | |
| SCHEMBL4434518 | 0.73 | — | — | |
| SCHEMBL10402389 | 0.73 | — | — | |
| SCHEMBL22008 | 0.73 | — | — | |
| SCHEMBL10402388 | 0.73 | — | — | |
| SCHEMBL4443156 | 0.72 | ALDH1A1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 325 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4275690-A2 | CROSSLINKED ARTIFICIAL NUCLEIC ACID ALNA | Mitsubishi Tanabe Pharma Corporation (JP) | 2023-11-15 | — | — | EP | claimed |
| EP-4275689-A2 | CROSSLINKED ARTIFICIAL NUCLEIC ACID ALNA | Mitsubishi Tanabe Pharma Corporation (JP) | 2023-11-15 | — | — | EP | claimed |
| US-11597745-B2 | β-modified phosphoric acid compound precursor, β-modified phosphoric acid compound, reaction inhibitor and medicine containing the same, and method for inhibiting reaction | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2023-03-07 | — | — | US | claimed |
| US-20220002336-A1 | CROSSLINKED ARTIFICIAL NUCLEIC ACID ALNA | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2022-01-06 | — | — | US | claimed |
| EP-3881851-A1 | CROSSLINKED ARTIFICIAL NUCLEIC ACID ALNA | Mitsubishi Tanabe Pharma Corporation (JP) | 2021-09-22 | — | — | EP | claimed |
| US-20200385722-A1 | 5' MODIFIED NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | IONIS PHARMACEUTICALS, INC. (US) | 2020-12-10 | — | — | US | claimed |
| US-20190290670-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | IDENIX PHARMACEUTICALS LLC (US) | 2019-09-26 | — | — | US | claimed |
| US-20190077726-A1 | METHODS OF SYNTHESIZING LABELED NUCLEOSIDES | SINGULAR GENOMICS SYSTEMS INC (US) | 2019-03-14 | — | — | US | claimed |
| US-20180251488-A1 | CROSSLINKED NUCLEIC ACID GUNA, METHOD FOR PRODUCING SAME, AND INTERMEDIATE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-09-06 | — | — | US | claimed |
| EP-3351548-A1 | CROSSLINKED NUCLEIC ACID GUNA, METHOD FOR PRODUCING SAME, AND INTERMEDIATE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-07-25 | — | — | EP | claimed |
| WO-2001014400-A1 | 2'-O-ACETAMIDO MODIFIED MONOMERS AND OLIGOMERS | ISIS PHARMACEUTICALS, INC. (US) | 2001-03-01 | — | — | WO | claimed |
| US-6172209-B1 | MOLECULAR HYBRIDIZATION, GENETIC ENGINEERING; NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS INC. | 2001-01-09 | — | — | US | claimed |
| US-6147200-A | NUCLEOSIDES FOR SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDES HAVING INCREASED NUCLEASE RESISTANCE AND BETTER BINDING AFFINITY; DIAGNOSIS; ANTISENSE THERAPY | ISIS PHARMACEUTICALS, INC. (US) | 2000-11-14 | — | — | US | claimed |
| US-6127533-A | SPECIFICALLY HYBRIDIZABLE WITH A SELECTED SEQUENCE OF RNA OR DNA; DIAGNOSIS OF DISEASES | ISIS PHARMACEUTICALS, INC. (US) | 2000-10-03 | — | — | US | claimed |
| US-5952478-A | Intermediates for dinucleotide and oligonucleotide analogues | NOVARTIS FINANCE CORPORATION (US) | 1999-09-14 | — | — | US | claimed |
| EP-0906327-A2 | INTERMEDIATES FOR OLIGONUCLEOTIDE SYNTHESIS | Novartis AG (CH) | 1999-04-07 | — | — | EP | claimed |
| WO-1997047636-A2 | INTERMEDIATES FOR OLIGONUCLEOTIDE SYNTHESIS | NOVARTIS AG (CH) | 1997-12-18 | — | — | WO | claimed |
| WO-1997035869-A1 | DINUCLEOTIDE AND OLIGONUCLEOTIDE ANALOGUES | NOVARTIS AG (CH) | 1997-10-02 | — | — | WO | claimed |
| EP-0778843-A1 | INTERMEDIATES FOR DINUCLEOTIDE AND OLIGONUCLEOTIDE ANALOGUES | Novartis AG (CH) | 1997-06-18 | — | — | EP | claimed |
| WO-1996008503-A1 | INTERMEDIATES FOR DINUCLEOTIDE AND OLIGONUCLEOTIDE ANALOGUES | NOVARTIS AG (CH) | 1996-03-21 | — | — | WO | claimed |